Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis

Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1456-62. doi: 10.1161/ATVBAHA.107.142539. Epub 2007 Mar 15.

Abstract

Objective: Tissue factor (TF) initiates coagulation and indirectly triggers thrombin-dependent protease activated receptor (PAR) signaling. The TF-VIIa complex also directly cleaves PAR2 and promotes angiogenesis in vitro in TF cytoplasmic domain-deleted (TF(deltaCT)) mice. Here we address the effect of PAR1 and PAR2 deficiency on angiogenesis in vivo.

Methods and results: In hypoxia-driven angiogenesis of oxygen induced retinopathy (OIR), wild-type, PAR1-/-, PAR2-/-, and TF(deltaCT) mice showed a comparable regression of the superficial vascular plexus during the initial exposure of mice to hyperoxia. However, TF(deltaCT) mice revascularized areas of central vaso-obliteration significantly faster than wild-type animals. Pharmacological inhibition of the TF-VIIa complex, but not of Xa, and blockade of tyrosine kinase receptor pathways with Gleevec reversed accelerated angiogenesis of TF(deltaCT) mice to revascularization rates observed in wild-type mice. Genetic deletion of PAR2, but not of PAR1, abolished enhanced revascularization of TF(deltaCT) mice. PAR1 knock-out animals were indistinguishable from wild-type mice in the model of retinal neoangiogenesis and angiogenesis-dependent subcutaneous tumor growth was unaltered in PAR1- and PAR2-deficient animals.

Conclusion: Loss of the TF cytoplasmic domain results in accelerated hypoxia-induced angiogenesis mediated by TF-VIIa signaling. PAR2 signaling is sufficient for this proangiogenic effect without apparent contributions of mouse host cell PAR1.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzamides
  • Blood Coagulation Factor Inhibitors / pharmacology
  • Cell Line, Tumor
  • Disease Models, Animal
  • Factor VIIa / metabolism
  • Hyperoxia / chemically induced
  • Hyperoxia / metabolism*
  • Hyperoxia / pathology
  • Hypoxia / complications*
  • Hypoxia / metabolism
  • Hypoxia / pathology
  • Imatinib Mesylate
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mice, Transgenic
  • Neoplasms, Experimental / blood supply
  • Neoplasms, Experimental / metabolism
  • Neoplasms, Experimental / pathology
  • Neovascularization, Pathologic / metabolism
  • Neovascularization, Pathologic / pathology
  • Oxygen
  • Piperazines / pharmacology
  • Protein Kinase Inhibitors / pharmacology
  • Pyrimidines / pharmacology
  • Receptor, PAR-1 / deficiency
  • Receptor, PAR-1 / genetics
  • Receptor, PAR-1 / metabolism*
  • Receptor, PAR-2 / deficiency
  • Receptor, PAR-2 / genetics
  • Receptor, PAR-2 / metabolism*
  • Retinal Neovascularization / etiology*
  • Retinal Neovascularization / metabolism
  • Retinal Neovascularization / pathology
  • Retinal Vessels / metabolism*
  • Retinal Vessels / pathology
  • Signal Transduction* / drug effects
  • Thromboplastin / genetics
  • Thromboplastin / metabolism*
  • Time Factors

Substances

  • Benzamides
  • Blood Coagulation Factor Inhibitors
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Receptor, PAR-1
  • Receptor, PAR-2
  • Imatinib Mesylate
  • Thromboplastin
  • Factor VIIa
  • Oxygen